Parvovirus Formulation Viscosity Control for Tumor Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic virus therapies face challenges with targeted distribution and stability, particularly experiencing backflow during administration and instability under storage conditions, which affects their efficacy in treating cancer.
Innovation Solution
A pharmaceutical composition comprising a parvovirus (such as H-1PV) in a carrier with 40-50% Iodixanol, 0.7-0.9 mmol CaCl2·2H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine, and 0.05-0.15 mg/ml Edetate calcium disodium, providing a viscosity of 3-5 mPa·s at 37-40°C, which ensures stable storage and prevents backflow during administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If oncolytic virus is administered using conventional carriers, then the virus can be delivered to the tumor, but backflow occurs during administration reducing targeted distribution
Solution Approach 1:
The patent changes the physical parameter of viscosity by formulating the carrier with 40-50% Iodixanol, which increases the viscosity to 3-5 mPa·s at 37-40°C. This parameter change prevents backflow during administration while maintaining targeted distribution to the tumor site.
Solution Approach 2:
The patent uses a composite carrier formulation combining Iodixanol with specific concentrations of salts (CaCl2, NaCl, KCl), Tromethamine, and Edetate calcium disodium. This composite material provides both the necessary viscosity to prevent backflow and chemical stability to maintain virus activity.
2Reliability
If oncolytic virus is stored under conventional conditions, then storage is simple, but the virus loses stability and activity over time
Solution Approach 1:
The patent changes the chemical environment parameters by incorporating specific concentrations of CaCl2 (0.7-0.9 mmol), NaCl (50-60 mmol), KCl (0.9-1.2 mmol), Tromethamine (0.7-0.95 mg/ml), and Edetate calcium disodium (0.05-0.15 mg/ml). These parameter changes create a stable chemical environment that preserves viral activity for at least 12 months.
Solution Approach 2:
The carrier components act as intermediaries that protect the virus from degradation. Specifically, the salts and chelating agents in the carrier formulation stabilize the viral structure and prevent degradation during storage, extending the duration of viral activity.
3Adaptability or versatility
If oncolytic virus is exposed to elevated temperatures, then storage flexibility increases, but viral activity decreases
Solution Approach 1:
The patent applies beforehand cushioning by incorporating stabilizing agents (Iodixanol, salts, Tromethamine, Edetate calcium disodium) into the carrier formulation before storage. This protective formulation cushions the virus against temperature fluctuations and UV exposure, maintaining viral activity even when stored at elevated temperatures.
4Object-affected harmful factors
If oncolytic virus is exposed to UV radiation, then sterilization is achieved, but viral activity is reduced
Solution Approach 1:
The carrier formulation with Iodixanol, salts, and chelating agents provides beforehand cushioning that protects the virus from UV-induced degradation. This protective environment allows the virus to withstand UV exposure while maintaining sufficient activity for therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves precise, targeted distribution and maintains viral stability for at least 12 months, even under elevated temperatures and UV exposure, enhancing the therapeutic effectiveness of parvovirus-based cancer treatments.
Implementation Method 1
The carrier has a viscosity between 3 to 5 mPa·s at 37° C. to 40° C.
Implementation Method 2
The virus multiplies preferentially in fast dividing cancer cells. This onco-selectivity is not based on a better uptake of the virus by cancerous cells, but rather is due to the fact that cancer cells overexpress factors, such as cyclin A, E2F, or CREB/ATF, required for virus DNA replication.
Data Source
AI summary
Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.